Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-PET/MRI Guided SBRT for Localized Prostate Cancer
NCT04243941Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Nov 2022; status: withdrawn.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04243941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243941.